Profile for European Patent Office Patent: 3390395
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Denmark | CA 2024 00006 | ⤷ Start Trial |
| Netherlands | 301262 | ⤷ Start Trial |
| Luxembourg | LUC00330 | ⤷ Start Trial |
| Lithuania | PA2024506 | ⤷ Start Trial |
| Denmark | CR 2024 00006 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 3390395
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 10,342,780 | Dec 16, 2036 | Loxo Oncol | JAYPIRCA | pirtobrutinib |
| 10,464,905 | Dec 16, 2036 | Loxo Oncol | JAYPIRCA | pirtobrutinib |
| 10,695,323 | Dec 16, 2036 | Loxo Oncol | JAYPIRCA | pirtobrutinib |
| 10,918,622 | Dec 16, 2036 | Loxo Oncol | JAYPIRCA | pirtobrutinib |
| 12,220,401 | Dec 16, 2036 | Loxo Oncol | JAYPIRCA | pirtobrutinib |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
